BCTX BRIACELL THERAPEUTICS CORP Other Situations 8-K Filing 2023 - FDA Meeting Feedback BriaCell Therapeutics Corp. announced positive feedback from its End of Phase II meeting with the FDA regarding its lead clinical candidate, Bria-IMT, in combination with a checkpoint inhibitor in advanced metastatic breast cancer.Get access to all SEC 8-K filings of the BRIACELL THERAPEUTICS CORP